Analyst Ranking
Search documents
The top 10 analysts of 2025, as measured by TipRanks
CNBC· 2026-01-25 12:47
Core Insights - The article highlights the top-performing analysts in the U.S. for the year 2025, as ranked by TipRanks based on their success rates and average returns [1][2]. Analyst Rankings - **Sam Slutsky – LifeSci Capital**: Achieved the highest ranking with a success rate of 67.74% and an average return of 62.4%. His notable recommendation on Abivax SA (ABVX) yielded a return of 894.81% [3]. - **Richard Shannon – Craig-Hallum**: Ranked second with a success rate of 61.87% and an average return of 36.9%. His top call on Aeva Technologies (AEVA) generated a return of 822.14% [4]. - **Joseph Stringer – Needham**: Secured the third position with a success rate of 79.17% and an average return of 38.2%. His best recommendation was for Inozyme Pharma (INZY), which returned 361.9% [5]. - **Myles Minter – William Blair**: Fourth place with a success rate of 66.93% and an average return of 28.8%. His top recommendation on Ovid Therapeutics (OVID) yielded a profit of 350% [6]. - **Ruben Roy – Stifel Nicolaus**: Fifth on the list with a success rate of 75.68% and an average return of 35.3%. His best call on CoreWeave (CRWV) generated a return of 293.2% [7]. - **Seamus Fernandez – Guggenheim**: Ranked sixth with a success rate of 78.57% and an average return of 40.6%. His best recommendation was for Cidara Therapeutics (CDTX), which returned 244.7% [8]. - **Thomas Smith – Leerink Partners**: Seventh place with an average return of 30.7% and a success rate of 65.22%. His best recommendation on Abivax yielded a return of 880.34% [9]. - **Mark Miller – Benchmark Co.**: Eighth with a success rate of 59.8% and an average return of 11.1%. His top call on SanDisk (SNDK) generated a return of 470.6% [11]. - **Allison Bratzel – Piper Sandler**: Ninth position with a success rate of 63.64% and an average return of 58.2%. His recommendation for Abivax also yielded a return of 894.81% [12]. - **Julian Harrison – BTIG**: Tenth with a success rate of 59.38% and an average return of 37%. His top recommendation on Abivax generated a return of 1,057.12% [13].